糖化终末产物对INS-1细胞基质金属蛋白酶2表达的影响

目的 探讨糖化终末产物(AGEs)对大鼠胰岛细胞株INS-1基质金属蛋白酶2(MMP-2)表达量的影响.方法 培养INS-1细胞,检测MMP-2表达;制备糖化胎牛血清,通过流式细胞仪检测细胞内活性氧簇(ROS)水平,通过逆转录PCR、实时定量PCR和Western印迹方法观察细胞中MMP-2表达量的变化.结果 INS-1细胞中存在MMP-2的表达;AGEs刺激后ROS明显升高(P<0.05),刺激组细胞内MMP-2mRNA表达量和蛋白表达水平均显著高于对照组(P<0.05).结论 提示胰岛β细胞内存在MMP-2表达,AGEs可诱导β细胞MMP-2表达量增高,MMP-2在介导胰岛氧化应激损伤中可能起着重要作用.

Abstract：

Objective To explore the impact of advanced glycation end-products ( AGEs) on matrix metalloproteinase 2 ( MMP-2) expression in cultivated INS-1 cells. Method INS-1 cells were cultivated and MMP-2 expression was analyzed. Glycated serum was prepared for incubating with INS-1 cell. Reactive oxygen species (ROS) was detected by flow cytometry. The intracelluar MMP-2 expression was analyzed by RT-PCR, realtime PCR and Western blot. The MMP-2 cDNA was expressed in cultivated INS-1 cells. Result The level of ROS treated with AGEs was significantly higher than that in the control( P<0.05 ) , and the levels of MMP-2 and its protein expressions turned out as well( P<0. 05). Conclusion The results suggest that MMP-2 was expressed in INS-1 cells. Increased MMP-2 expression in ?cells may be induced by AGEs, suggesting that MMP-2 might play an important role in oxidative stress-mediated islet injury.     

糖化终末产物对INS-1细胞基质金属蛋白酶2表达的影响

目的 探讨糖化终末产物(AGEs)对大鼠胰岛细胞株INS-1基质金属蛋白酶2(MMP-2)表达量的影响.方法 培养INS-1细胞,检测MMP-2表达;制备糖化胎牛血清,通过流式细胞仪检测细胞内活性氧簇(ROS)水平,通过逆转录PCR、实时定量PCR和Western印迹方法观察细胞中MMP-2表达量的变化.结果 INS-1细胞中存在MMP-2的表达;AGEs刺激后ROS明显升高(P<0.05),刺激组细胞内MMP-2mRNA表达量和蛋白表达水平均显著高于对照组(P<0.05).结论 提示胰岛β细胞内存在MMP-2表达,AGEs可诱导β细胞MMP-2表达量增高,MMP-2在介导胰岛氧化应激损伤中可能起着重要作用.     

糖基化终末产物对大鼠肾皮质基质金属蛋白酶2活性和表达的影响

的　研究糖基化终末产物 (AGEs)对肾皮质基质金属蛋白酶 2 (MMP 2 )活性及其mRNA表达的影响。方法　用链脲佐菌素制备大鼠糖尿病模型。大鼠血清蛋白与 0 .5mol/L葡萄糖孵育制备AGEs,分静脉注射AGEs(AGEs组 )、静脉注射大鼠正常血清 (阴性对照组 )和未注射大鼠 (对照组 ) 3组进行观察。ELISA测定肾皮质和血清AGEs含量 ,RT PCR检测MMP 2、金属蛋白酶组织抑制物 2 (TIMP 2 )mRNA表达水平 ,酶谱法测定MMP 2活性。结果　糖尿病大鼠肾皮质AGEs含量明显升高 ,MMP 2mRNA表达下降 ,TIMP 2mRNA表达上调 (均P <0 .0 1)。AGEs处理组大鼠肾皮质AGEs含量明显升高 (P <0 .0 1) ,MMP 2活性也明显下降 (均P <0 .0 5)。结论　AGEs通过降低大鼠肾皮质MMP 2的活性及其mRNA表达及增加TIMP 2mRNA表达 ,由此减少肾小球细胞外基质 (ECM )降解 ,可能是导致糖尿病肾病ECM积聚的原因之一     

细胞内基质金属蛋白酶2基因过表达对INS-1细胞功能的影响

目的探讨细胞内基质金属蛋白酶2(MMP-2)基因过表达对大鼠胰岛β细胞株INS-1细胞功能的影响。方法采用基因重组技术将大鼠MMP-2cDNA插入真核表达载体pcDNA 3.1(+)构建大鼠MMP-2真核表达质粒,培养INS-1细胞。随机分为正常对照组,空质粒转染组及MMP-2质粒转染组。脂质体Lipofectmine 2000转染INS-1细胞,观察INS-1细胞内MMP-2基因和蛋白表达量变化,MMP-2酶活性变化,以及INS-1细胞凋亡情况与胰岛素分泌功能的变化。结果与正常对照组、空质粒转染组比较,MMP-2质粒转染组MMP-2mRNA表达增加(P均0.05),蛋白表达水平和酶活性上调(P均0.05);MMP-2质粒转染组细胞凋亡率(56.07±3.68)%高于正常对照组(33.70±6.53)%及空质粒转染组(38.02±5.60)%(P0.05),而IRI(1.30±0.27)低于正常对照组(3.37±0.76)与空质粒转染组(2.90±0.84)(P0.05)。结论细胞内MMP-2基因的过表达可引起胰岛β细胞凋亡增加,胰岛素分泌功能下降。     

糖化终末产物与氧化应激及血管病变

葡萄糖与含氨基生物分子(主要为蛋白质,也包括核酸和脂类)可发生复杂的反应,最后形成一类结构复杂的化合物,称为糖化终末产物(advanced glycation end products,AGEs)。AGEs结构极为复杂,与很多病理生理过程密切相关。     

分泌型糖化终末产物受体与糖尿病并发冠心病的关系

在高糖环境中，蛋白质或脂质经长时间糖化形成晚期糖化终末产物。有研究证实，后者与糖尿病进展及心脑血管并发症关系甚为密切。糖化白蛋白（GA）是体内一种早期糖化终末产物，可促进糖尿病血管并发症的发生和发展。内源性分泌型糖化终末产物受体（esRAGE）是糖化终末产物受体的一种剪接变体，通过与晚期糖化终末产物结合，中和后者的病理作用。本研究旨在探讨esRAGE和GA水平与2型糖尿病并发冠心病及其严重性的关系。     

晚期糖化终末产物在糖尿病大鼠骨质疏松发病中的作用

目的：探讨晚期糖化终末产物（ＡＧＥ）在糖尿病骨质疏松发病中的作用。方法用链脲佐菌素制做糖尿病大鼠模型,３个月后测定大鼠腰椎骨密度及骨胶原中ＡＧＥ的含量及观察血、尿生化指标的变化。结果糖尿病大鼠骨胶原中ＡＧＥ的含量与正常对照组相比明显升高（Ｐ〈０．００１）,而骨密度明显降低（Ｐ〈０．０２）。２４ｈ尿钙增加,血钙降低。结论糖尿病大鼠骨胶原中ＡＧＥ含量的增加所导致的成骨作用降低,可能是糖尿病骨质疏松发病     

糖化终末产物对MIN6细胞活力及活性氧(ROS)水平的影响

探讨糖化终末产物(AGE)对小鼠胰岛细胞株MIN6细胞活力及活性氧(ROS)水平的影响.制备BSA-AGE,用不同浓度AGE(100、200、400 mg/L)干预MIN6细胞不同时间后,MTF比色法检测细胞活力变化.以活性氧捕获剂双氢-乙酰乙酸二氯荧光黄(DCFH-DA)孵育细胞,通过流式细胞仪检测细胞内二氯荧光黄(DCF)的荧光强度而测得细胞内活性氧水平,并测定胰岛素分泌的变化.随着AGE浓度的升高和作用时间的延长,细胞活力明显下降(P＜0.05).经DCFH-DA孵育后流式细胞仪检测显示,AGE处理组细胞内DCF平均荧光强度较对照组明显升高(P＜0.05).胰岛素分泌量随着AGE浓度的增高和时间的延长,呈下降趋势(P＞0.05).提示BSA-AGE抑制MIN6活力,使细胞内活性氧生成增加,诱导MIN6细胞氧化应激.

Abstract：

To explore the effect of advanced glycation end-products(AGEs)on cell viability and level of reactive oxygen species(ROS)in MIN6 cells. After intervention of various concentrations(100,200, and 400 mg/L)of AGEs for some time, cell viability was detected by MTT assay. 2', 7'-dichlorofluorescein diacetate(DCFH-DA)was used as a reactive oxygen species capture agent. The fluorescent intensity of 2', 7'-dichlorofluorescein(DCF), which was the product of cellular oxidation of DCFH-DA, was detected by flow cytometry. The level of ROS and insulin secretion was thus measured. Viability of MIN6 cells was inhibited by AGEs in a dose and time dependent manner(P＜0.05).Intracellular fluorescent intensity of DCF was markedly elevated in the AGEs groups as compared with that in the control group(P＜0.05).Insulin secretion was decreased in the AGEs groups than that in the control group(P＞0.05). The results suggest that AGEs inhibit the viability and induce oxidative stress in MIN6 cells by overproduction of ROS.     

瑞舒伐他汀对血管平滑肌细胞基质金属蛋白酶2表达和细胞迁移的影响

目的 观察瑞舒伐他汀对同型半胱氨酸(Hcy)诱导大鼠血管平滑肌细胞基质金属蛋白酶2(MMP 2)表达以及对血管平滑肌迁移的影响,探讨Hcy致动脉粥样硬化以及他汀药物逆转的可能机制.方法 体外培养大鼠主动脉平滑肌细胞,加入不同浓度的Hcy分别作用 24 h、48 h和72 h,在1000 μmol/L Hcy浓度下分别加入不同浓度的瑞舒伐他汀干预,采用免疫印迹法和明胶酶谱法检测细胞培养上清液中MMP 2的表达及酶的活性.在Transwell小室外室中加入1000 μmol/L浓度的Hcy,内室加入定量的大鼠平滑肌细胞悬液,培养48 h,观察Hcy对平滑肌细胞迁移侵袭力的影响;同时加入不同浓度瑞舒伐他汀溶液,分别培养24 h、48 h和72 h,观察瑞舒伐他汀对Hcy诱导平滑肌细胞迁移侵袭力的影响.结果 Hcy浓度在50～5000 μmol/L时促进血管平滑肌细胞MMP 2蛋白的表达,Hcy浓度在50～1000 μmol/L时增强血管平滑肌细胞MMP 2的酶活性,浓度在5000 μmol/L时抑制MMP 2的活性(F值分别为9.31、6.44、5.97,均P＜0.05);瑞舒伐他汀浓度在10-9～10-5 mol/L时,能抑制Hcy对血管平滑肌MMP 2表达和酶活性的增强作用(F值分别为3.92、4.78、2.14,均P＜0.05).Hcy在50～5000 μmol/L浓度下能刺激血管平滑肌细胞迁移,Hcy浓度为0、50、100、500、1000、5000 μmol/L时平滑肌细胞迁移分别为(18.32±2.17)个、(32.68±4.34)个、(44.75±4.08)个、(61.39±5.21)个、(79.74±5.54)个 和(90.78±5.83)个(F=5.31,P＜0.05);而瑞舒伐他汀可以抑制Hcy对血管平滑肌细胞迁移的刺激作用,在瑞舒伐他汀浓度为10-9、10-8、10-7、10-6、10-5 mol/L时平滑肌细胞迁移分别为(79.74±5.54)个、(62.53±6.41)个、(48.37±5.66)个、(31.41±4.79)个、(19.27±3.62)个和(11.17±2.33)个(F=4.99,P＜0.05).结论 Hcy能影响血管平滑肌细胞MMP 2蛋白的表达,瑞舒伐他汀能抑制Hcy对血管平滑肌细胞MMP 2的表达和酶活性的增强作用,并能抑制Hcy对血管平滑肌细胞迁移的刺激作用,这可能是瑞舒伐他汀抗动脉粥样硬化的作用机制之一.

Abstract：

Objective To observe the effects of rosuvastatin on the homocysteine (Hcy)-induced expression of matrix metalloproteinase 2 (MMP 2) and cell migration in rat vascular smooth muscle cells (VSMCs), and to explore the possible mechanism of Hcy-induced atherosclerosis and the role of statins in reversing atherosclerosis. Methods In one cell culture plate, the cultured rat VSMCs were incubated with different concentrations of Hcy (0, 50, 100, 500, 1000 μmol/L and 5000 μmol/L) in vitro for 24 h, 48 h and 72 h. And in another cell culture plate, the different concentrations of rosuvastatin (10-9, 10-8, 10-7, 10-6, 10-5 mol/L and 0 mol/L) were added to the cultured rat VSMCs (while the concentration of Hcy was 1000 μmol/L). The MMP 2 expression and enzyme activity were determined by gelatin zymography and Western blotting. The effects of Hcy and rosuvastatin on cell migration and invasiveness of VSMCs were observed. Results Hcy (50-5000 μmol/L) increased the protein expression, and Hcy (50-1000 μmol/L) increased enzyme activity of MMP 2 significantly. But Hcy (5000 μmol/L) inhibited activity of MMP 2 (F=9.31, 6.44 and 5.97, all P＜0.05). Rosuvastatin (10-9-10-5 mol/L) inhibited Hcy-induced expression and enzyme activity increasing of MMP 2. The counts of cell migration of VSMCs were 18.32±2.17, 32.68±4.34, 44.75±4.08, 61.39±5.21, 79.74±5.54 and 90.78±5.83, while the concentration of Hcy was 0, 50, 100, 500, 1000 μmol/L and 5000 μmol/L respectively (F=5.31, P＜0.05). The counts of cell migration of VSMCs were 79.74±5.54, 62.53±6.41, 48.37±5.66, 31.41±4.79, 19.27±3.62 and 11.17±2.33, while the concentration of rosuvastatin was 10-9, 10-8, 10-7, 10-6 and 10-5 mol/L respectively (F=4.99, P＜0.05). Rosuvastatin could decrease the stimulation of Hcy-induced migration of VSMCs. Conclusions Hcy can influence the MMP 2 protein expression/activity in VSMCs, and rosuvastatin can inhibit augmentation of Hcy-induced MMP 2 expression/activity and migration of VSMCs. It may be one of the multiple-effects of rosuvastatin reducing atherosclerosis.     

2型糖尿病高血压患者血浆内源性分泌型晚期糖基化终末产物受体和氧化应激的关系

探讨2型糖尿病高血压患者血浆内源性分泌型晚期糖基化终末产物受体(esRAGE)与氧化应激的关系.结果 显示2型糖尿病患者esRAGE与体重指数(BMI,r=-0.33)、舒张压(r=-0.38)、氧化应激均显著相关(均P相似文献   

晚期糖基化终末产物对小鼠骨髓干细胞向血管内皮细胞分化的影响

观察晚期糖基化终末产物(AGEs)对骨髓干细胞(BMSC)向内皮细胞分化的影响.结果 发现,20μg/ml AGEs对BMSC分化的影响不明显,100μg/ml AGEs使BMSC分化能力明显下降,血管内皮生长因子受体2阳性细胞计数和百分数均明显降低.     

血清基质金属蛋白酶9、糖基化终产物与糖尿病足的相关研究

比较糖尿病足患者(糖尿病足组)、2型糖尿病但非糖尿病足患者(非糖尿病足组)及健康体检者血清基质金属蛋白酶9(MMP-9)、晚期糖基化终产物(AGE)水平.糖尿病患者MMP-9、AGE水平高于健康者,糖尿病足组MMP-9高于非糖尿病足组.血清MMP-9升高似可预测糖尿病足发生及足溃疡的预后.     

糖基化终产物对人血管内皮细胞基质金属蛋白酶-2表达和活性的影响

目的探讨糖基化终产物(AGEs)对人血管内皮细胞ECV304基质金属蛋白酶-2(MMP-2)表达和活性的影响。方法应用AGEs作用ECV304细胞后,采用RT-PCR法及明胶酶图分析方法分析MMP-2表达和活性与AGEs浓度和时间的关系。结果 RT-PCR结果显示,AGEs能够诱导ECV304细胞表达MMP-2,其诱导表达具有浓度和时间依赖性(P<0.01)。明胶酶图分析显示,MMP-2降解明胶的活性与AGEs具有浓度依赖性。结论 AGEs能够促进ECV304细胞MMP-2的表达和活性,推测AGEs调控MMP-2表达和活性可能在血管壁内皮细胞影响动脉粥样硬化的进展中发挥一定的作用。     

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes

Aims/hypothesis Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE in humans. We investigated the impact of improving glycaemic control on serum total sRAGE and endogenous secretory RAGE (esRAGE), a splice variant of sRAGE, and compared the effect of rosiglitazone with that of sulfonylurea. Methods A randomised, open-label, parallel group study was performed with 64 participants randomised to receive add-on therapy with either rosiglitazone or sulfonylurea. Serum total sRAGE and esRAGE and metabolic parameters were measured before and after 6 months of treatment. Results At 6 months, both rosiglitazone and sulfonylurea resulted in a significant reduction in HbA_1c, fasting glucose and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the rosiglitazone group. As a result, serum esRAGE was higher in the rosiglitazone group than in the sulfonylurea group at 6 months (p < 0.01), whereas the differences in sRAGE between the two groups did not reach statistical significance. Stepwise linear regression analysis showed that treatment modality made a greater contribution than the changes in HbA_1c to the subsequent changes in esRAGE levels at 6 months. Conclusions/interpretation Treating type 2 diabetic patients with thiazolidinedione can increase circulating levels of esRAGE and sRAGE. Whether modulation of circulating sRAGE has a beneficial effect on diabetic complications will have to be evaluated in long-term prospective studies. International Standard Randomised Controlled Trial Number ISRCTN05215453.     

晚期糖基化终产物及其受体在白细胞中表达与老年人精神障碍的关系

目的 探讨血液中晚期糖基化终产物(AGEs)及其受体(RAGE)表达水平与老年人精神障碍性疾病的关系. 方法 将观察对象分为健康对照组31例、阿尔茨海默病(AD)组36例、血管性痴呆组20例、脑血管病所致精神障碍组28例.以荧光分光光度法测定各组血清AGEs水平,以逆转录多聚酶链式反应测定RAGE mRNA水平. 结果 血清AGEs水平在AD组、血管性痴呆组和精神障碍组分别为(477.1±36.2)AU/ml、(512.6±33.2)AU/ml和(415.25±32.5)AU/ml,均明显高于健康对照组(357.4±28.2)AU/ml(F=3.77,P<0.05).RAGE mRNA水平(RAGE/b-actin)分别为1.12±0.34、1.27±0.41和1.18±0.42,亦高于健康对照组的0.92±0.37(F=4.07,P<0.01),但各疾病组间差异无统计学意义(F=0.979,P>0.05).白细胞中RAGE mRNA水平与血清AGEs呈正相关关系(r=0.442,P<0.01). 结论 AD、血管性痴呆、脑血管病所致精神障碍患者血中的AGEs及其受体RAGE mRNA水平均较同龄健康老年人明显升高,AGEs与RAGE的相互作用可能直接或间接参与了老年人精神障碍性疾病的病理变化.     

晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的关系

晚期糖基化终末产物(AGE)是高血糖的标志物,能通过AGE受体(RAGE)发挥致病作用.研究发现,AGE/RAGE与非酒精性脂肪性肝病(NAFLD)的发展关系密切.AGE能增加肝脏的甘油三酯水平,促进单纯性脂肪肝(SFL)的发生,AGE/RAGE可诱导肝脏炎性反应,促进SFL向非酒精性脂肪性肝炎(NASH)发展,并能通过诱导活性氧簇的合成,活化肝脏星状细胞来引起肝纤维化.